Acute Leukemia/Myelodysplastic syndrome
Conditions
Interventions
Azacitidine treatment group:Azacitidine
Decitabine treatment group:Decitabine
Sponsors
Ningbo First Hospital
Eligibility
Sex/Gender
All
Age
14 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Allogeneic hematopoietic stem cell transplantation in patients with confirmed AML/high-risk MDS; 2. The age range is 14-70 years old (including 14 years old and 70 years old); 3. Expected survival period >= 3 months; 4. Good organ function level: no abnormal function of important organs such as heart, lung, liver and kidney, and can withstand high-dose chemotherapy; 5.ANC (absolute neutrophil value >= 0.5x10^9/L; PLT >= 50 x 10^9/L); 6. From the end of receiving any anti-tumor therapy (including radiotherapy, chemotherapy, surgery or molecular targeted therapy) to participation in the washout period of this trial ?4 weeks. No current GVHD and no previous history of grade 3 or above aGVHD; 7. Voluntarily participate in this clinical trial, understand the research procedures and be able to sign the informed consent in writing.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating patients; 2. Previously known allergic or resistant to azacitidine or decitabine; 3. Investigators evaluate those who cannot tolerate super-strong conditioning regimens; 4. Other reasons for not being selected by the investigator's evaluation; 5. Severe active infection, the investigator evaluates those who cannot tolerate preconditioning.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| minimal residual disease;immature cells;overall survival;relapse-free survival; | — |
Countries
China
Contacts
Public ContactZhang Ping/Ouyang Guifang
Ningbo First Hospital
Outcome results
None listed